More relevant and reliable preclinical cardiotoxicity tests are required to improve drug safety and reduce the cost of drug development. Current in vitro testing strategies predominantly take the form of functional assays to predict the potential for drug-induced ECG abnormalities in vivo. Cardiotoxicity can also be structural in nature, so a full and efficient assessment of cardiac liabilities for new chemical entities should account for both these phenomena. As well as providing a more appropriate nonclinical model for in vitro cardiotoxicity testing, human stem cell-derived cardiomyocytes offer an integrated system to study drug impact on cardiomyocyte structure as well as function. Employing human embryonic stem cell-derived cardiacmyocytes (hESC-CMs) on 3 assay platforms with complementary insights into cardiac biology (multielectrode array assay, electrophysiology; impedance assay, cell movement/beating; and high content analysis assay, subcellular structure) we profiled a panel of 13 drugs with well characterized cardiac liabilities (Amiodarone, Aspirin, Astemizole, Axitinib, AZT, Bepridil, Doxorubicin, E-4031, Mexiletine, Rosiglitazone, Sunitinib, Sibutramine, and Verapamil). Our data show good correlations with previous studies and reported clinical observations. Using multiparameter phenotypic profiling techniques we demonstrate the dynamic relationship that exists between functional and structural toxicity, and the benefits of this more holistic approach to risk assessment. We conclude by showing for the first time how the advent of transparent MEA plate technology enables functional and structural cardiotoxic responses to be recorded from the same cell population. This approach more directly links changes in morphology of the hESC-CMs with recorded electrophysiology signatures, offering even greater insight into the wide range of potential drug impacts on cardiac physiology, with a throughput that is more amenable to early drug discovery.
Cardiotoxicity is one of the most prevalent forms of druginduced toxicity (Stevens and Baker, 2009 ). Failure to predict cardiovascular liability prior to clinical trials or launch has resulted in numerous costly late stage drug development failures and market withdrawals. To mitigate this risk, the pharmaceutical industry has adopted a range of assays to probe the cardiac liability of compounds earlier in the drug development process consistent with the mantra "fail faster, fail cheaper." These tests predominantly take the form of functional assays to assess the potential for acute drug-induced ECG abnormalities. Such assays typically employ primary heart cells and tissue, immortalized mammalian cardiac cell lines, or heterologous systems expressing specific cardiac ion channels typically in noncardiac cell backgrounds.
In addition to altering the acute mechanical function of the heart (functional toxicity), cardiotoxicity can also occur due to morphological damage to cardiomyocytes, changes to intracellular organelles, or loss of cardiomyocyte viability (structural toxicity), resulting in cardiomyopathy and heart failure (Laverty et al., 2011; Pointon et al., 2013) . Consequently, the full and efficient assessment of cardiac liabilities for new chemical entities should not be restricted to electrophysiological analysis of drug effects on hERG and other ion channels, but should ideally take a more holistic account of both the structural and functional aspects of cardiac cell biology.
A major limitation of the current disparate range of in vitro and ex vivo models in use today is that none can be utilized as a single test system across both structural and functional cardiotoxicity assays to generate a cohesive risk assessment. Recent advances in methods for large-scale production of cardiomyocytes (CM) from human embryonic stem cells (hESC) and induced pluripotent stem cells, together termed human stem cell-derived cardiomyocytes (hSC-CMs), offers an opportunity to provide a human model system that is amenable to high throughput screening. As well as providing a more relevant nonclinical model for in vitro cardiotoxicity testing, these cells have the potential to bridge analytical platforms and in doing so provide an integrated model for probing many possible causes and mechanisms of cardiotoxicity.
There are now over a hundred reports in the literature demonstrating the utility of hSC-CM across a wide range of analytical platforms. These instruments enable a variety of assays to be performed using hSC-CM which are informative of drug impact on diverse aspects of cardiac biology including electrophysiology (Becker et al., 2013; Caspi et al., 2009; Peng et al., 2010) , calcium transients (Lewis et al., 2015; Sirenko et al., 2013) , contractility (Agarwal et al. 2013) , cell movement/beating (Guo et al., 2013) , metabolic activity (Rana et al., 2012) , morphology, and viability (Pointon et al., 2013; Thomas, 2012) . Several studies in the literature have successfully employed complementary assays utilizing hSC-CMs to probe cardiotoxicity (Doherty et al., 2013; Pointon et al., 2013; Talbert et al., 2015; Thomas, 2012) , but it remains to be demonstrated whether the outputs of these assays could be combined into a single well.
In this study, we selected 3 assay platforms on the basis that each offered a distinct insight into cardiac biology with a throughput amendable for early drug discovery: multielectrode array (MEA) assay to track drug-induced effects on hESC-CM electrophysiology; impedance assay for changes in cell movement (hereafter referred to as beating) and cell viability; and high content analysis (HCA) assay for perturbations in cell morphology. The MEA assay is an electrophysiology-based technique which uses microelectrodes embedded in the culture surface of each well to measure fluctuations in extracellular field potential (FP) generated from spontaneously beating hSC-CM. The resulting FP waveform is analogous to an in vivo ECG trace, which measures the change in voltage on the body surface generated by ionic currents that flow through the heart. By measuring the drug-mediated impact on multiple features of the FP signal in the hSC-CM MEA assay, the cardiac liability and mechanism of action of a compound can be predicted (Clements and Thomas, 2014) . This hSC-CM MEA assay is an element of the ongoing Comprehensive in vitro ProArrhythmia Assay (CiPA) initiative to obviate the need for clinical thorough QT studies with an integrated in vitro and in silico approach (Cavero and Holzgrefe, 2015; Gintant, 2014; Sager et al., 2014; Zhang et al., 2014) .
As a result of excitation-contraction coupling, the electrical stimulus, measured in the MEA assay, is converted into the mechanical contraction of the cardiomyocyte. The physical movement of a layer of beating cardiomyocytes can be continuously monitored with the impedance assay by means of specially designed microelectrode plates. The recorded impedance signal is reflective of the phasic changes in cell contact with the recording electrode and consequently reflects cell movement rather than providing a measure of contractility. Application of this hSC-CM impedance assay has been demonstrated as an effective model to predict drug-induced arrhythmia (Guo et al., 2013) .
Preservation of cell morphology is fundamental to the basal function of the cardiomyocyte. HCA using high-throughput fluorescence microscopy and automated image analysis, in combination with specific probes to key indicators of cardiomyocyte function such as mitochondrial integrity and calcium homeostasis, provides a multiparameter approach to the study of cardiotoxic liabilities of compounds (Pointon et al., 2013; Thomas, 2012) . Imaging events at the subcellular level allow nonion channel drug effects to be probed, revealing information on the mode of action of cardiotoxic drugs.
Here we have profiled 13 compounds with wellcharacterized cardiac liabilities in side-by-side comparison of the 3 aforementioned assays and demonstrate the complementary nature of their endpoints. The panel of compounds tested includes 2 drugs which are considered noncardiotoxic (Aspirin and Axitinib), 5 which perturb function (Bepridil, E-4031, Mexiletine, and Verapamil through design, Astemizole due to off-target effects), 3 which are structural toxins (AZT, Doxorubicin, and Rosiglitazone), and 3 which have both structural and functional mechanisms of toxicity (Amiodarone and Sunitinib directly, Sibutramine indirectly via a peripheral sympathomimetic effect). Furthermore, using a transparent 48-well MEA plate we demonstrate for the first time that it is possible to follow hSC-CM MEA recordings with a post hoc HCA assay. This approach allows functional and structural cardiotoxic responses to be recorded from the same cell population, offering even greater insight into the wide range of potential drug impacts on cardiac physiology.
MATERIALS AND METHODS
Cell culture. Human embryonic stem cell-derived cardiomyocytes (Cytiva Plus; GE Healthcare) were thawed in RPMI 1640/B27 (Life Technologies) medium following the manufacturer's recommended protocol. The hESC-CM stock cell suspension was then used to plate MEA, impedance, and HCA assay plates in parallel.
MEA assay. MEA 48-well plates (Axion BioSystems) were prepared by pipetting 4 ml droplets of fetal bovine serum (FBS) onto each electrode region and incubating for 1.5 h at room temperature. Following adsorption of FBS to the surface the droplet was replaced with 4 ml fibronectin solution (12.5 mg/ml, BD Biosciences) and plates incubated at 37 C for 2 h. Cytiva Plus CMs were seeded direct from thawed cryovials onto prepared MEA plates using 4 ml of cell suspension at 1.5 Â 10 7 viable cells/ml (60 000 cells per well) in RPMI 1640/B27 medium. Once cell attachment was complete (2-3 h) 400 ml RPMI 1640/B27 medium was carefully added to the well taking care not to disturb the plated cells. The plates were then incubated at 37 C/5%
CO 2 . Every 24 h after plating, FP measurements were recorded from spontaneously beating hESC-CM monolayers using a Maestro MEA system (Axion BioSystems) at 37 C. The MEA plate was placed on the preheated MEA system for 10 min to allow the spontaneous activity to equilibrate, followed by a recording of 100 s of extracellular FP data at the end of the period. On days 3 and 5 postthaw half the seeding medium was replaced with fresh medium and cells were used for compound dosing experiments on day 6 postthaw (Fig. 1) .
Impedance assay. hESC-CMs were seeded directly from thawed cryovials onto fibronectin-coated E-Plate Cardio 96 well plates (ACEA Biosciences Inc) at 50 000 viable cells per well in 180 ml RPMI 1640/B27 medium. Every 24 h after plating, beating (beat period) and viability (Cell Index) were recorded from spontaneously beating hESC-CM monolayers using an xCELLigence RTCA Cardio system (ACEA Biosciences Inc) at 37 C/5% CO 2 . The E-Plate plate was placed on the xCELLigence system for 30 min to allow the spontaneous activity to equilibrate, followed by a recording of 40 s of impedance data at the end of the period. Half the culture medium was replaced with fresh medium every day and cells were used for dosing experiments on day 6 postthaw ( Fig. 1) . Test compound stocks were prepared as described above for the MEA assay. These compound stocks were equilibrated to 37 C before diluting 1:8 into the E-Plate to give a final medium volume of 202.5 ll/well. Impedance recordings of spontaneous activity were taken 4, 24, 48, and 72 h postdosing (sampling rate of 77 Hz) and analyzed using RTCA Cardio Software V1.0.
High content image analysis (HCA) assay. hESC-CMs were seeded directly from thawed cryovials onto fibronectin-coated 384-well plates (Greiner mClear) at 8000 viable cells per well in 30 ml RPMI 1640/B27 medium. Since this is an end-point assay, 4 identical plates were set-up, 1 for each of the compound exposure time-points of interest (4, 24, 48, or 72 h) . On days 3 and 5 postthaw the seeding medium was replaced with fresh medium and cells were used for dosing experiments on day 6 postthaw (Fig. 1) . Test compound stocks, prepared in DMSO or dH 2 O at 1000-fold above the highest tested concentration, were serially diluted in RPMI 1640/B27 medium to 2Â target concentration. These compound stocks were equilibrated to 37 C before Combined MEA and HCA assay. Transparent MEA (tMEA) 48-well plates (Axion BioSystems) were prepared using the method described for the regular MEA 48-well plate above. Test compounds were added to wells of the tMEA plate to give the indicated final compound concentrations (10 nM, 1 mM, 10 mM). FP recordings of spontaneous activity were taken 4, 24, and 48 h postdosing and analyzed using AxIS software V2.0.2.9. Immediately after acquisition of the 48 h timepoint, the hESCCMs were stained with the Cytiva Cell Health Assay for HCA kit (GE Healthcare) by direct addition to the contents of the well, and incubated at 37 C for 1 h. Images were acquired using an IN Cell Analyzer 2200 (GE Healthcare) with a 40Â objective at 37 C.
Image analysis was performed using IN Cell Developer V1.9.3 (GE Healthcare).
Drug. Amiodarone, Aspirin, Astemizole, AZT (3 0 -Azido-3 0 -deoxythymidine), Bepridil, Doxorubicin, E-4031, Mexiletine, Sibutramine, Sunitinib, and Verapamil were purchased from Tocris (Bristol, UK). Axitinib, (-)-Blebbistatin, DMSO, and Rosiglitazone were purchased from Sigma-Aldrich (Dorset, UK).
Data analysis. All data collected were used to generate mean data. Statistical analysis was performed using Prism V4.03 (GraphPad) and hierarchical clustering of multiparameter data was performed using Spotfire Decision Site 9.1.1 (TIBCO). All assessments of drug impact are t tests versus time-matched DMSO vehicle controls. 
RESULTS

Recovery of Cryopreserved hESC-CM From Thaw
Before studying the effects of test compound on hESC-CMs, the optimal post-thaw recovery period for the cryopreserved cells was established. The spontaneous beating characteristics of the hESC-CMs were evaluated every 24 h postthaw with the MEA assay and every hour with the impedance assay at 37 C. The MEA assay measures fluctuations in extracellular FP generated from spontaneously beating hSC-CMs. Multiple features of the FP signal were tracked during the postthaw recovery period including the magnitude of the sharp transient associated with Na þ influx (spike amplitude), beat period, and the FP duration (FPD) a correlate of action potential duration (Fendyur and Spira, 2012 ; Fig. 2A ). The impedance signal is reflective of the phasic changes in cell contact with the recording electrode during the physical contraction and relaxation cycle of the cardiomyocyte (Abassi et al., 2012) . Consequently, the impedance signal reflects cell movement rather than providing a measure of contractility. Changes in the spontaneous beat period were monitored during the postthaw recovery period with the impedance assay (Fig. 2Bi ).
After 37.1 6 1.5 h (n ¼ 60) in culture the hESC-CMs began to beat spontaneously (data not shown). Between days 2 and 6 postthaw the spontaneous beating properties of the cells developed with time in culture as demonstrated by an increase in beat period ( Fig. 3 ; MEA, 1.30 6 0.13 s vs 1.62 6 0.24 s, P > .001, paired t test, n ¼ 133; impedance, 1.30 6 0.12 s vs 1.89 6 0.26 s, P > .001, paired t test, n ¼ 100), FPD (342 6 42 ms vs 548 6 84 ms, P > .001), and FPDcF (0.313 6 0.035 vs 0.467 6 0.060, P > .001). Furthermore, the number of electrodes in a given MEA well detecting a FP signal in this period also increased (9.8 6 3.2 s vs 13.2 6 2.6 s, P > .001) which could be interpreted as an increase in size of the beating syncytium as the cells electrically couple together. No significant changes in recorded parameters were observed between days 4 and 5 postthaw. Consequently, a 6-day postthaw recovery period was employed prior to dosing the cells with test compounds.
Functional and Structural Assays Provide Complementary Insights
Into Mechanism of Cardiotoxicity Drug-induced cardiotoxicity can be the result of both acute changes in the mechanical function of the heart (functional toxicity), or morphological damage to cardiomyocytes (structural toxicity). Numerous assays have been developed capable of tracking either of these outcomes in hSC-CM models. In an effort to provide a more comprehensive assessment of cardiac liabilities for the drugs tested in this study, we utilized 3 assay platforms with complementary insights into cardiac physiology: MEA assay to track drug-induced effects on hESC-CM electrophysiology; impedance assay for changes in beating and cell viability; and HCA assay for perturbations in cell morphology. The measured parameters for the MEA assay were identical to those recorded above. In addition to the spontaneous beat period in the impedance assay, cell index (CI), an indirect measure of cell viability was also recorded (Figs. 2A and 2B). Structural toxicity was investigated through HCA of live-cell fluorescent images of hESC-CM nuclear size, cytoplasmic [Ca 2þ ], mitochondrial number (count) and area, and cell viability (Fig. 2C ). Only data from viable (live) cells were used to calculate cell morphology measures. Nonviable (dead) cells were used to calculate the proportion of viable cells in a well ( Fig. 2D and see Supplementary Fig. 1 for more details).
Thirteen compounds with well-characterized cardiac liabilities were studied in a side-by-side comparison of the 3 aforementioned assays, of which 2 are considered non-cardiotoxic (Aspirin and Axitinib), 5 perturb function (Bepridil, E-4031, Mexiletine, and Verapamil through design, Astemizole due to off-target effects), 3 are structural toxins (AZT, Doxorubicin, and Rosiglitazone), and 3 have both structural and functional mechanisms of toxicity (Amiodarone and Sunitinib directly, Sibutramine indirectly via a peripheral sympathomimetic effect; see Table 1 ). The drug-induced effects were assessed at 3 concentrations (10 nM, 1 mM, 10 mM) and followed over a 72-h period postdosing.
Noncardiotoxic Drugs
Compounds considered noncardiotoxic (Aspirin and Axitinib) did not perturb the spontaneous electrophysiological characteristics of the hESC-CMs in the MEA assay at any of the concentrations tested during the duration of the experiment (vs time-matched DMSO control; Fig. 4 and Supplementary Fig. 2 ). Similarly, Aspirin had no effect on the hESC-CM spontaneous beat rate as determined by impedance measurements. Axitinib did however, suppress spontaneous beating and reduced CI at the highest concentration tested 72 h postdosing (P > .001, t test), although this is >33 000-fold greater than the free drug concentration of 0.3 nM. As expected, neither Aspirin (Figs. 5A and 6) nor Axitinib ( Supplementary Fig. 3 ) exposure produced a change in the structural parameters (nuclear size, cytoplasmic [Ca 2þ ], mitochondrial number and area, and cell viability) recorded in the HCA assay.
Functional Cardioactive Drugs
The antihistamine, Astemizole, was withdrawn from the market in 1997 due to drug-induced ventricular arrhythmia (Torsades de Pointes; TdP), a result of delayed cardiac repolarization caused by off-target hERG K þ channel block. Drug-induced delays in cardiac repolarization can be observed as the prolongation of the FPD in the MEA assay, measured from the initial Na þ spike to the maxima of the K þ depolarization wave ( Fig. 2A) . Accordingly, Astemizole prolonged FPD and FPDcF at 10 nM (P > .001, t test) and suppressed spontaneous activity at higher concentrations, consistent with previous observations (Fig. 4; Clements and Thomas, 2014) . Likewise, Astemizole concentrations !1 mM also suppressed spontaneous beating in the impedance assay, with the highest concentration tested producing a significant reduction in CI at 24-h postdosing (P > .001, t test). CI generated from the impedance signal profiles have been used as an indication of cell viability and cytotoxicity ( Fig. 2Bii ; Xing et al., 2006) . This Astemizole-induced reduction in cell viability was confirmed with the HCA assay. Imaging events at the subcellular level allow nonion channel drug liabilities to be probed, revealing information on the mode of action of cardiotoxic drugs (Pointon et al., 2013; Thomas, 2012) . Astemizole (10 mM) simultaneously increased intracellular calcium concentration and reduced mitochondrial count and area (P > .001, t test, 24 h) with no significant change in nuclear area (Figs. 5B and 6). E-4031 is a selective hERG K þ channel blocker that is used for research purposes only. Consistent with previous findings, E-4031 prolonged FPD and FPDcF at 10 nM (P > .01, t test) and suppressed spontaneous activity at 10 mM (Supplementary Fig.  2 ; Clements and Thomas, 2014) . Like Astemizole, this loss of spontaneous activity at the highest concentration tested was accompanied by a change in both mitochondrial count and cell viability HCA structural measures, though to a far lesser extent (P > .01, t test, 48 h; Supplementary Fig. 3 ).
Mexiletine, a Class Ib antiarrhythmic, acts by blocking sodium channels. The sharp transient spike in the FP waveform ( Fig. 2A) is associated with Na þ influx and membrane depolarization. Appropriately, Mexiletine (10 mM) suppressed spontaneous activity 4 h postdosing consistent with blockade of an excitatory current. Spontaneous activity resumed by 24 h postdosing, although with reduced FP spike amplitude (P > .01, t test, 48 h) and prolonged beat period (P > .001, t test, 48 h; Fig. 4 ). An equivalent response was observed in the recorded beat period of the impedance assay (P > .001, t test, 48 h). Consistent with Mexiletine's absence of structural toxic effects, none of the structural measures recorded in the HCA assay were altered by exposure to Mexiltine (Figs. 5C and 6).
The anti-angina, Bepridil, was withdrawn from the market in 2004 due to TdP. Bepridil is generally classed as a Ca 2þ channel blocker (IC 50 ¼ 1.0 mM) yet has a variety of other actions including hERG K þ channel block (IC 50 ¼ 0.16 mM). In both MEA and impedance assays, spontaneous activity was unperturbed by 10 nM Bepridil, but completely suppressed by !1 mM within 4-h postdosing ( Supplementary Fig. 2 ). Bepridil has been shown to induce a small ($20%) but not significant prolongation in FPD in iPSC-CMs at 10 mM (Kaneko et al., 2014) . We repeated the MEA assay using a further 2 test concentrations, 100 and 300 nM, in an attempt to observe this Bepridil-induced delayed repolarization. As expected, Bepridil prolonged FPD versus DMSO control at 300 nM (17% increase, P > .05, t test, 48 h, Supplementary Fig. 4 ). Human ESC-CMs treated with 1 mM Bepridil resumed spontaneous activity by 48-h postdosing, although with reduced FP spike amplitude (P > .01, t test, 48 h) and a prolonged beat period, which was statistically significant in the impedance assay (P > .01, t test, 48 h; Fig. 4 ). There was no recovery in spontaneous activity in cells treated with 10 mM Bepridil, and this concentration was found to reduce mitochondrial count, area, and cell viability (P > .001, t test, 48 h) in the HCA assay ( Supplementary Fig. 3 ). Supplementary Fig. 4 ). Concentrations !1 mM suppressed spontaneous activity within 4 h postdosing ( Supplementary Fig. 2) . At the highest concentration tested (10 mM), there was a corresponding change in both mitochondrial count and cell viability HCA structural measures (P > .01, t test, 48 h; Supplementary  Fig. 3 ).
Structural Cardiotoxins
The broad-spectrum anti-tumor drug, Doxorubicin, is associated with congestive heart failure (CHF) and a decrease in left ventricular ejection fraction (LVEF) due to changes in contractility. Spontaneous activity in the MEA assay was suppressed 24-h postdosing with 10 mM Doxorubicin, and 48-h postdosing with 1 mM (Fig. 4) . Comparable results were found when Doxorubicininduced effects on spontaneous cell beating were recorded in the impedance assay (Fig. 5) . The loss in cell function is coincident with reduction in CI in the impedance assay and a loss of mitochondria and cell viability in the HCA assay (Figs. 5D and 6). This result would suggest that the loss of hESC-CM spontaneous beating was the result of structural cardiotoxicity and not Doxorubicin's identified ion channel effects (Ducroq et al., 2010) . AZT (3 0 -Azido-3 0 -deoxythymidine) is a nucleoside analog reverse-transcriptase inhibitor (NRTI) used for the treatment of HIV-1, which postmarketing has been associated with an increased incidence of CHF. Although relatively rare, this AZTinduced cardiotoxicity is thought to be the result of mitochondrial damage due to mitochondrial DNA depletion (McKee et al., 2004) . Since only mitochondrial biogenesis is affected, longterm treatment with AZT is required before mitochondria are depleted enough to significantly reduce ATP synthesis. In this study, AZT had no effect on the recorded hESC-CM spontaneous electrophysiological characteristics or structural measures at any of the concentrations tested during the duration of the experiment (vs time-matched DMSO control; Supplementary  Figs. 2 and 3) . Rosiglitazone is an antidiabetic drug associated with an increased risk of CHF and myocardial infarction. Consequently, in 2010 the EMA recommended Rosiglitazone be withdrawn from the European market. At supertherapeutic levels (10-30 mM), Rosiglitazone has been shown to induce cardiac contractile dysfunction due to oxidative stress-induced mitochondrial dysfunction (He et al., 2015) . However, in this study Rosiglitazone failed to perturb any of the hESC-CM electrophysiological, beating, or structural measures recorded in this study ( Supplementary Figs. 2 and 3 ).
Functional and Structural Cardiotoxins
Sunitinib, a tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma, is known to have both functional (delayed cardiac repolarization and TdP) and structural (e.g. decreased LVEF) cardiac liabilities. Consistent with Sunitinib's effects on cardiac repolarization, 1 mM prolonged FPD (P > .001, t test, 4 h) and FPDcF (P > .01, t test, 4 h), and this effect persisted throughout the 72-h exposure period (Fig. 4) . A concurrent increase in beat period was observed in both MEA and impedance assays (P > .001, t test). At the highest concentration tested (10 mM) Sunitinib suppressed spontaneous activity in the MEA assay within 4 h of dosing. This loss of activity was accompanied by a large increase in cytoplasmic calcium concentration in the HCA assay (P > .001, t test, 4 h), prior to a loss of mitochondria and cell viability (P > .001, t test, 24 h; Figs. 5E and 6), consistent with Sunitinib's demonstrated mitochondrial toxicity (Chu et al., 2007; Cohen et al., 2011) . Amiodarone is also associated with both functional and structural cardiotoxicity. It is generally considered a Class III Amiodarone is also known to have structural cardiac liabilities including CHF. In both MEA and impedance assays, spontaneous activity was unperturbed by 10 nM Aminodarone, but completely suppressed by 1 mM within 4-h postdosing (Fig. 4) . To test whether Amiodarone's known effects on cardiac repolarization could have been captured had an intermediate concentration been tested in this study (e.g. $7% increase in FPDcF at 300 nM;
Nozaki et al., 2014) we repeated the MEA assay using a further 2-test concentrations, 100 and 300 nM. 300 nM Amiodarone induced a modest (12%) but not significant increase in FPD 24-h post-dosing, which was followed by a significant increase in beat period (P > .05, t test, 48 h) and decrease in spike amplitude (P > .001, t test, 48 h; Supplementary Fig. 4 ). The highest concentration tested (10 mM) reduced CI 24-h postdosing (P > .05, t test) which corresponded to a loss of cell viability as determined by the HCA assay (P > .001, t test). Amiodarone (10 mM) preferentially reduced mitochondrial count and area (P > .001, t test, 24 h) prior to nuclear swelling (P > .05, t test, 48 h; Figs. 5F and 6). The former result is concordant with Amiodarone exhibiting mitochondrial toxicity (Ká lai et al., 2005) .
The appetite suppressant, Sibutramine, was used for the treatment of obesity but was withdrawn from the market in 2010 because of an increased risk of adverse cardiovascular events. Sibutramine exerts a peripheral sympathomimetic effect, which induces a moderate increase in heart rate (tachycardia) which can result in myocardial infarction. At supertherapeutic levels, Sibutramine has been shown to block the cardiac ion channels, hERG K þ , Cav1.2, and Nav1.5 with IC 50 s of 8.6, 9.7, and 27 mM, respectively (Kim et al., 2008) . Sibutramine (10 mM) suppressed spontaneous activity 4-h postdosing which then resumed after 24 h in both the MEA and impedance assays ( Supplementary Fig. 2 ). This transient suppression could have been the result of multiple ion channel block. As expected, no increase in beat rate (ie, reduction in beat period) was observed since no noradrenergic input was present. Sibutramine also failed to perturb any HCA structural measures or viability ( Supplementary Fig. 2 ).
Multiparameter Analysis of Drug-Induced Effects
Although analysis of a single assay measure alone can be informative, a single parameter is not adequately descriptive of the often complex effects of drugs in modulating cardiac biology. The multiassay multiparameter approach described above allows for a detailed characterization of drug impact on cardiomyocyte physiology, including complex perturbations that develop with concentration and/or duration of exposure. A challenge with so much data, however, becomes how best to compile it into a format that can be readily interpreted. This is especially true if the approach were to be suitable for use in a screening environment. Parallel coordinate plots (Wegman, 1990) allow complex drug dose effects on hSC-CM physiology to be visualized and classified by drug effects on key functional (Clements and Thomas, 2014) and structural (Thomas, 2012) parameters.
To provide a more complete picture of drug-induced effects we graphed the measures from all 3 assays on a single parallel coordinate plot with functional parameters on the left and structural parameters on the right (Fig. 7A ). In the selected example, 24-h postdrug, 10 nM Astemizole perturbed, and 1 mM suppressed spontaneous activity, but both concentrations had no impact on recorded cardiomyocyte structural measures. At the highest concentration tested (10 mM), however, Astemizole showed structural toxicity and reduced cell viability (Figs. 7A and 7C) .
From the wider set of parallel coordinate plots it can be observed that (i) Aspirin had no significant effect on any of the recorded functional or structural parameters at any of the concentrations tested during the duration of the experiment (Fig. 7B) ; (ii) 1 mM Mexiletine perturbed, and 10 mM suppressed spontaneous activity, with little impact on recorded cardiomyocyte structural measures (Fig. 7D) ; (iii) Doxorubicin-induced loss of spontaneous activity as a rule coincided with the perturbation of recorded structural measures and developed with drug concentration and period of exposure (Fig. 7E) ; (iv) 1 mM Sunitinib perturbed, and 10 mM suppressed spontaneous activity, with the higher concentration exhibiting increased structural toxicity with time in drug (Fig. 7F) ; and (v) !1 mM Amiodraone suppressed spontaneous activity and 10 mM induced structural toxicity (Fig. 7G) .
Combined MEA and HCA Assay in a Transparent 48-Well MEA Plate Here we have demonstrated how functional and structural assays can provide complementary insights into the mechanism of cardiotoxicity. It would be advantageous, however, if both these assays could be performed in the same well on the same population of cells. This approach would allow changes in recorded electrophysiology signature to be directly linked with hSC-CM subcellular structure. Until now, the electrodecontaining base of disposable multiwell format MEA plates suitable for screening purposes have been opaque, restricting their use in imaging applications. Recent advancements in microelectrode fabrication have enabled production of electrode arrays encased in a transparent substrate. The resultant tMEA plates should now in theory enable hSC-CMs to be imaged in the well. It remains to be determined, however, whether the subcellular features probed in HCA can be resolved in these tMEA plates.
To test the feasibility of a combined MEA and HCA assay, hESC-CMs were cultured in tMEA plates (Axion BioSystems) as described previously for the standard (opaque) MEA plate (see Materials and Methods section for more details). Standard MEA plates and 384-well imaging plates, for separate MEA and HCA assays, respectively, were also prepared in order to provide time-matched data for comparative purposes (Fig. 8 ). Cells were challenged with test compound (Aspirin, Astemizole, Doxorubicin, or Sunitinib) at 3 test concentrations (10 nM, 1 mM, and 10 mM). The drug-induced effects in the tMEA and MEA plates were then accessed at 4, 24, 48-h postdrug application (data not shown). Immediately after acquisition of the 48-h time-point, hESC-CMs in the tMEA and 384-well plates were imaged using the HCA assay ( Supplementary Fig. 5 ). Despite the relative thickness of the tMEA plate base [1.10 mm, vs 190 mm for 384-well plates (Greiner mClear)] detailed structures such as mitochondrial filaments could still be resolved in the HCA assay (Figs. 8D and 8E) .
In order to validate this combined structural and functional cardiotoxicity assay, the MEA and HCA data collected from the tMEA plate were compared with the time-matched separate MEA and HCA assay controls (referred to as Exp#2), and the data from the previous set of experiments (referred to as Exp#1). Data from the respective MEA and HCA assays were again graphed on a single parallel coordinate plot with functional parameters on the left and structural parameters on the right (Fig. 9A) . The parallel coordinate plots generated from the tMEA data (Fig. 9C) were comparable to both the time-matched separate MEA and HCA assay controls (Fig. 9D ) and the data from the initial round of experiments (Fig. 9B) .
It has previously been demonstrated that hierarchical clustering of multiparameter MEA data sets based on Euclidian distance can be employed as an unbiased method of grouping compounds with similar ion channel activities (Clements and Thomas, 2014) . Since hierarchical clustering groups parallel coordinate plots with similar phenotypic profiles, we used this method to test whether the combined MEA and HCA data set generated from tMEA plates is comparable to that produced in separate assays. The multiparametric MEA and HCA data from the tMEA plate clustered with analogous data from separate MEA and HCA assays indicating that the data produced by the 2 methods are comparable (Fig. 10A) . Furthermore, the dataset clusters into 5 recognizable groups: drug concentrations that (i) fail to perturb function or structure ( ). This dataset demonstrates that the MEA assay can resolve changes in functional state but not structural state, and the HCA assay vice versa (Fig. 10B) .
The analyses reported here indicate that the combination of functional and structural toxicity data derived from multiparameter hSC-CM MEA and HCA assays, respectively, could provide an even greater insight into the wide range of potential drug impacts on cardiac physiology. Consequently, this approach could hold significant promise for enabling more predictive risk assessment in drug discovery.
DISCUSSION
Cardiotoxicity is a major cause of compound attrition in preclinical and clinical drug development. More relevant and reliable in vitro tests are required to improve early stage assessments of drug hazard and more accurately predict cardiac liabilities in vivo. Drug-induced cardiotoxic effects can be functional or structural in nature so a cell model capable of studying both these phenomena would be preferable. A major limitation of the current in vitro and ex vivo models in use today is that none can be utilized as a single test system across both structural and functional cardiotoxicity assays to generate a cohesive risk assessment. The introduction of assays utilizing hSC-CMs could potentially address the shortcomings of these existing models.
In this study, we utilized hESC-CMs on 3 assay platforms with complementary insights into cardiac biology (MEA assay, electrophysiology; impedance assay, beating and cell viability; and HCA assay, subcellular structure) to profile a panel of drugs with well-characterized cardiac liabilities. To integrate the analysis of the multiparameter datasets from these 3 assays we used multiparameter analysis methods more commonly used for microarray data assessment. These multiassay parallel coordinate plots revealed complex dose-exposure effects on the dynamic relationship between cardiomyocyte functional and structural toxicity, demonstrating the benefits of this more holistic approach to risk assessment.
Overall our data show good correlations with previous studies and reported clinical observations (Table 1) , but there were some notable exceptions. Amiodarone lengthens the cardiac action potential and is used clinically as an antiarrhythmic agent. Previously amiodarone (300 nM) has been show to induce a modest prolongation of FPDcF in iPSC-CMs ($7%, Nozaki et al., 2014) . In this study, Amiodarone also induced a modest (12%) increase in FPD 24-h postdosing, but this effect was not significant. At higher drug concentrations spontaneous activity was FIG. 9 . Validating a combined structure-function hESC-CM toxicity assay. A, Example parallel coordinate plot generated from a combined MEA and HCA assay in a 48-well tMEA plate. Vertical arrows indicate drug-induced changes to recorded measures 48 h after 10 nM Astemizole application (green line) versus DMSO control (black line). B, Parallel co-ordinate plots for Aspirin, Astemizole, Doxorubicin, and Sunitinib acquired 48 after dosing. Data from first round of separate MEA and HCA assays displayed again for comparative purposes (illustrated in Fig. 8 ; referred to as Exp#1). C, Subsequent data from the combined MEA and HCA assay performed in a tMEA plate; and D, time-matched separate MEA and HCA assay controls (referred to as Exp#2). Vehicle control (DMSO; black); 10 nM (green), 1 mM (blue), and 10 mM (red). n.d. ¼ not determined. suppressed ( Supplementary Fig. 4 ). The selective hERG K þ channel blockers, E-4031 and astemizole, however produced the expected robust prolongation in FPD (Fig. 4) , in agreement our previous findings for drugs with Class III antiarrhythmic type properties (e.g. dofetilide and sotalol; Clements and Thomas, 2014) . This discrepancy could be in part due to multiion channel block, ie, Amiodarone's effect on hERG is offset by its actions at other cardiac ion channels (e.g. Cav1.2 and NaV1.5).
The structural cardiotoxins, AZT and Rosiglitazone, have both been shown to induce cardiotoxicity as a result of mitochondrial damage, but neither drug perturbed the mitochondrial nor cell viability measures in the HCA assay. However, AZT-induced cardiotoxicity is observed with prolonged use, and the extent of increased cardiovascular risk associated with Rosiglitazone use is still a matter for debate. Cells cultured in glucose culture media, as in this study, generate ATP , 2015, Vol. 148, No. 1 predominantly by glycolysis (the Crabtree effect) and consequently may be partially or wholly resistant to mitochondrial mechanisms of toxicity (Li et al., 2014) . Consequently, culturing hSC-CMs in a medium that shifts cellular metabolism to oxidative phosphorylation, which is more reflective of cellular metabolism in vivo, could increase the toxicity of AZT and Rosiglitazone in this assay. It is also worth noting that Sibutramine failed to induce the increase in beat rate or associated structural toxicity in these hESC-CM assays. This was to be expected however, since Sibutramine's cardiotoxic effects occur indirectly via blocking noradrenaline reuptake and no noradrenergic input was present in the assay. The result highlights the point that the hSC-CM assays described here can only be used to detect direct modes of cardiotoxicity.
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The number of test concentrations employed in an assay is a compromise between assay throughput and acquisition of transitory perturbed states. We utilized 3 test concentrations (10 nM, 1 mM, and 10 mM) to probe the mechanism(s) of druginduced cardiotoxicity. In general, these 3 test concentrations captured the predicted cardiotoxic responses, but with 3 notable exceptions. Amiodarone, Bepridil, and Verapamil each required additional intermediate test doses (e.g. 100 and 300 nM) to resolve perturbed functional states before spontaneous activity was suppressed by higher drug concentrations ( Supplementary  Fig. 4) . Consequently, the inclusion of these intermediate test concentrations would be required in the assay to ensure that these transient states are captured and subsequently the mechanism of cardiotoxicity more accurately defined.
The data presented here also demonstrate that concentration selection is critical in order to differentiate between functional and structural effects. For example, Astemizole, Axitinib, Bepridil, and Verapamil are not considered functional structural cardiotoxins, but induced structural toxicity at the highest concentration tested (10 mM) as determined by the HCA assay. However, if the sensitivity threshold for structural toxicity is defined as a !20% change in one or more HCA assay structural measures within 24 h of drug exposure, only Amiodarone, Doxorubicin, Sunitinib would be identified as being structural toxins at 1000 of the free drug concentration (Amiodarone ¼ 2-fold; Doxorubicin ¼ 0.3; Sunitinib ¼ 770). As discussed above, AZT, Rosiglitazone, and Sibutramine failed to induce structural toxicity in the HCA assay.
Furthermore, functional cardioactive drugs in this study could be defined as inducing significant changes to one or more of the recorded FPD, FPDcF, or spike amplitude MEA assay functional measures at concentrations 100-fold of the free drug concentration. This would identify Astemizole (33-fold), Bepridil (10), Mexieltine (2), Sunitinib (77), and Verapamil (1) as functional cardioactive drugs. E-4031 could not be included in this analysis due to the lack of clinical pharmacokinetic data. Whether this functional cardioactive property is perceived as a risk would depend on the intended use for the compound. Using these reasoning, compounds with functional and structural effects would meet both selection criteria described above (e.g. Sunitinib).
The analysis outlined above is dependent upon clinical pharmacokinetic data which may not be available for new chemical entities. In such an instance any assessment of toxicity associated risk for a compound would be based on its relative potency in the assay alone. The challenge, as above, is to strike an appropriate balance between weeding out undesirable compounds whilst limiting the unnecessarily removal of promising compounds which are in fact safe. From the data generated in this study it is possible however to speculate the threshold for a no observable effect level for the hESC-CM MEA and HCA assays. For example, a compound could be defined as a potential structural cardiotoxin, if at a concentration of 10 mM it induces a !20% change in one or more HCA assay structural measures within 24 h of exposure. These criteria would correctly identify Amiodarone, Doxorubicin, and Sunitinib as being potential structural cardiotoxins, and inappropriately Astemizole, whilst excluding compounds like Axitinib, Bepridil and Verapamil. Similarly, a compound could be defined as a potential functional cardioactive compound, if at a concentration of 10 mM it induces a !15% change in one or more of the recorded FPD, FPDcF, or spike amplitude MEA assay functional measures within 24 h of exposure. This threshold would correctly identify Astemizole, Bepridil, E-4031, Mexiletine, Sunitinib, and Verapamil, but incorrectly exclude Amiodarone.
Each of the 3 hSC-CM assays used in this study provided a complementary perspective of the drug-induced cardiotoxic effects of the compounds tested. The MEA assay records extracellular FP waveforms from the spontaneously beating hSC-CMs which are analogous to clinical ECG recordings. These transients are data rich providing information on the FPD, an in vivo analogue of the QT interval, spike amplitude, associated with Na þ influx, as well as descriptors of beat rate and regularity.
Profiling drug-induced effects on these multiple features of the FP transient can be used to predict the identity of the impacted ion channel(s) (Clements and Thomas, 2014) . The power of this analysis will undoubtedly strengthen as more information is gleaned from the FP signal (e.g. repolarization hump decay-rate; Vicente et al., 2015) . This FP transient cannot, however, be used to decipher whether a loss of spontaneous activity was the result of functional (e.g. suppression of excitability, 10 mM Mexiletine) or structural (e.g. loss of cell viability, 10 mM Doxorubicin) toxicity. The impedance transient lacks the subtlety of the FP wave to report partial ion channel block effects. For example, the effects of Na þ channel block by 1 mM Mexiletine were observable as a reduction in spike amplitude in the MEA assay without a comparable perturbation in the impedance signal (Figs. 4 and 5) . Likewise, the drug-induced increase in FPD by 10 nM Astemizole associated with no change in beat period was also not detected in the impedance assay (Figs. 4 and 5) . Impedance-based hSC-CM assays typically focus on tracking compound-induced changes to beat rate and regularity (Guo et al., 2013) . Oftentimes, drug impact on these measures of chronicity and regularity correlates with the analogous features in the MEA assay, as demonstrated in this study. However, cardiomyocyte movement measures can offer additional insights into drug liability for compounds that perturb the contractile machinery, without impacting the cell's electrophysiology (Abbasi et al., 2012) . For example, in our hands the myosin II inhibitor Blebbistatin (10 mM) suppressed spontaneous hESC-CM beating within 4 h of dosing (as determined by brightfield imaging in tMEA plates using IN Cell Analyzer 2200) without perturbing the recorded MEA and HCA assay measures (data not shown). An additional benefit of the impedance assay is that the output signal (CI) can be used as an approximate measure of cell viability (Xing et al., 2006) . In this study we found that CI positively correlated with cell viability as determined by HCA (r 2 ¼ 0.797, data not shown). It is perhaps unsurprising that there is not a stronger correlation between the HCA cell viability measure and CI, since CI will be influenced by changes to numerous cell features including morphology, cell adhesion to CLEMENTS ET AL. | 257 the electrode, cell number, and cell size. Nevertheless, analysis of both beating and CI measures can be used together to predict whether a loss of spontaneous beating is the result of functional (no simultaneous decrease in CI, e.g. 1 mM Astemizole) or structural (concomitant decrease in CI, e.g. 10 mM Doxorubicin; Fig. 4 ) toxicity (Guo et al., 2013) . HCA using high-throughput fluorescence microscopy and automated image analysis, in combination with specific probes to key indicators of cardiomyocyte structure such as mitochondrial integrity and calcium homeostasis, provides a multiparameter approach to the study of cardiotoxic liabilities of compounds. Measuring numerous structural parameters simultaneously can be mechanistically insightful by identifying the parameter modulated at the lowest concentration (Pointon et al., 2013; Thomas, 2012) . As a result, this single cell resolution of cell health is far more descriptive of drug-induced structural toxicity than the impedance assay's CI measure. For instance, both 1 mM Doxorubicin and 10 mM Amiodarone induced a reduction in CI in the impedance assay, but their respective HCA data profiles are quite different. The loss of cell viability in Doxorubicin was associated with an increase in cytoplasmic Ca 2þ concentration and decrease in mitochondrial measures, whereas in Amiodarone, nuclear swelling accompanied the loss of mitochondria (Fig. 6 ). Unlike the label-free MEA and impedance assays however, HCA requires addition of fluorescent dyes to the well. Consequently, the progression of toxicity with exposure time cannot be tracked in the same population of cells (ie, multiple wells are required). The HCA assay utilized in this study was designed to track structural toxicity, so it is perhaps unsurprising that changes to hESC-CM spontaneous beating properties (ie, functional toxicity) were not detected. For example, 10 nM, and 1 mM Astemizole treatment produced identical HCA parallel coordinate plots, whereas in the MEA assay, 10 nM Astemizole prolonged FPD and 1 mM suppressed spontaneous activity. However, HCA assays that profile cell surface nutrient transporter expression in hESC-CMs have been demonstrated to be predictive of metabolic modulation induced by drug toxicity (Li et al., 2014) . Since the energetic demands required by a spontaneously beating versus a nonbeating cardiomyocyte are likely to be greater, the hSC-CM nutrient transporter expression profile might be able to resolve drug-induced changes to spontaneous beat rate.
When employed together, functional and structural assays can provide complementary insights into the mechanism of cardiotoxicity. For higher throughput applications it would be desirable if both these assays could be performed in the same well. Not only would this be more convenient and cost-effective, but would allow changes in recorded electrophysiology signature to be directly linked with hSC-CM structure. Several groups have successfully developed assay platforms capable of acquiring FP and impedance recordings from the same well (Abassi, 2014; Doerr et al., 2015) , enabling drug-induced effects on hSC-CM excitability to be linked with observed changes in beating. This combined analysis of FP and cell movement on an integrated instrument may offer some additional insights into drug liability for compounds such as Blebbistatin which interfere with the cardiomyocyte contractile machinery but may not directly impact the cell's electrophysiology as measured by MEA. Nevertheless, it remains to be seen whether such examples of drug action are widespread and justify parallel voltage and cell movement analysis. Perhaps more importantly, these dual MEA and impedance recordings offer the ability to link drug-induced changes in cardiomyocyte electrophysiology with a measure of cell viability (CI), allowing one to speculate whether the root cause was functional or structural in nature (see above).
In this study, we demonstrate that a combination of MEA and HCA assay endpoints would provide a more detailed account of drug impact on cardiac physiology than the combined MEA-impedance assay described above. Using transparent multiwell MEA plates suitable for screening applications we assessed the feasibility of performing FP recordings and a post hoc HCA assay on the same population of cells in the same well. Here, we show that the combined MEA and HCA dataset generated from the tMEA plate is comparable to that produced in separate assays. This approach allows a spectrum of drug-induced changes to both functional and structural parameters to be observed in a single well, not possible with either assay alone (Fig. 10B ).
The HCA assay described can be performed post-MEA assay, by simple addition of the 4 dyes to the well followed by fluorescent imaging. As a result, this assay lends itself to a more informed and flexible approach to toxicity testing, whereby the results in the MEA assay could influence whether a post hoc HCA test is required. For instance, if hSC-CM spontaneous beating was not perturbed by test compound application in the MEA assay the data above suggest a subsequent HCA test would be negative for structural toxicity. However, if the compound of interest suppressed spontaneous activity in the MEA assay, the hSC-CMs could be stained for indicators of cardiomyocyte structure, to determine if/how subcellular structures (e.g. mitochondria) in these cells had been impacted.
Our study illustrates the utility of complementary MEA and HCA screening assays to assess functional and structural cardiac liabilities in parallel. Subsequent multiparametric data analysis provides high-throughput profiling of drug-impact on numerous features of cardiac physiology. This form of analysis may prove useful in identifying drug cardiac liabilities in a screening environment allowing new candidate drugs to be classified and ranked with respect to cardiac liability in the absence of clinical drug exposure data. At later stages in drug development, when therapeutically effective free drug concentrations have been established, re-examination of this dataset in conjunction with clinical exposure data could help refine risk predictions. In conclusion, this approach has the potential to facilitate informed decision making and liability management at the optimum point in drug development.
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